Rasmus T Hoeg

Title(s)Associate Professor of Clinical, MED: Int Med HMCTBMT
SchoolSchool of Medicine
AddressCancer Center
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis. Blood Adv. 2026 May 26; 10(10):3543-3553. Mascarenhas J, Fogliatto L, Green S, Corvalan I, Traer E, Kirito K, Chuah H, Sakatoku K, Hoeg R, Khawandanah M, Lavie D, Hunter Z, Quinn D, Wang Y, Harb J, Zha J, Malyankar U, Ritchie E. PMID: 41843794.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23; 147(17):2011-2017. Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS. PMID: 41643192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177. Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. PMID: 41385341; PMCID: PMC13123417.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis. Blood Adv. 2026 02 24; 10(4):1153-1162. Tuscano JM, Othman T, Frankel P, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde EL, Mei M, Rosenberg AS, Hoeg RT, Costello C, Foss FM, William BM, Holland HK, Sharon E, Streicher H, Danilov AV, Newman E. PMID: 41213001; PMCID: PMC12917533.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis. Blood Adv. 2026 Feb 24; 10(4):1153-1162. Tuscano JM, Othman T, Frankel P, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde EL, Mei M, Rosenberg AS, Hoeg RT, Costello C, Foss FM, William BM, Holland HK, Sharon E, Streicher H, Danilov A, Newman E. PMID: 41733958.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    6. CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood Adv. 2026 Jan 13; 10(1):276-288. Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH. PMID: 41052404; PMCID: PMC12848364.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    7. Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 10; 23(10). Loren AW, Mielcarek M, Bolaños-Meade J, Brammer J, Cowden M, Di Stasi A, El-Jawahri A, Elmariah H, Gundabolu K, Gutman J, Ho V, Hoeg RT, Horwitz M, Jamy O, Kassim A, Kharfan-Dabaja M, Lee L, Logan A, Luszcak C, Magenau JM, Martin TG, Mittal V, Moreira J, Muffly L, Nakamura R, Nawas M, Nieto Y, Ninos C, Oliai C, Papanicolaou G, Pidala J, Randolph B, Schroeder MA, Tessier J, Topal J, Tzachanis D, Varshavsky-Yanovsky AN, Jones F, Stehman K. PMID: 41067275.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. Leuk Res Rep. 2025; 24:100541. Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel AB. PMID: 40917153; PMCID: PMC12409799.
      View in: PubMed   Mentions:
    9. The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 Nov; 60(11):1465-1471. O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. PMID: 40849364; PMCID: PMC12583187.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility. Ophthalmol Sci. 2026 Jan; 6(1):100905. Park SS, McCormack J, Salazar D, King JS, Salvador M, Bauer G, Fury B, Abedi M, Moshiri A, Macias D, Moussa K, Kondapaka R, Lindblad R, Hoeg R, Nolta JA. PMID: 41693811; PMCID: PMC12902143.
      View in: PubMed   Mentions:
    11. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May; 10(5):105081. Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Barragan-Carrillo R, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. PMID: 40315659; PMCID: PMC12098135.
      View in: PubMed   Mentions: 1  Translation:Humans
    12. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147. Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. PMID: 39093952; PMCID: PMC11707416.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 02 10; 43(5):558-566. Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L, ROCCA Consortium. PMID: 39418622; PMCID: PMC12070553.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    14. Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. J Oncol Pharm Pract. 2025 Oct; 31(7):1046-1050. Tsao M, Hoeg R, Pecoraro J, Kuehner M, Deen B, Guglielmo J. PMID: 39155604; PMCID: PMC12426334.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma. Bone Marrow Transplant. 2023 10; 58(10):1143-1145. Othman T, Lowsky R, Richman C, Hoeg R, Abedi M, Tuscano J. PMID: 37391654.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 02; 21(2):108-115. Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. PMID: 36791762.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 08; 119:106885. Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 35738024.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    18. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 01; 63(1):231-234. Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. PMID: 34486920.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplant. 2021 12; 56(12):2975-2980. Pham B, Hoeg R, Krishnan R, Richman C, Tuscano J, Abedi M. PMID: 34471239; PMCID: PMC8636264.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    20. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021; 11:649209. Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 33777810; PMCID: PMC7991747.
      View in: PubMed   Mentions: 33  
    21. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e611-e618. Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. PMID: 33811007.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 04 01; 96(4):E114-E117. Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. PMID: 33476436.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    23. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021 01 07; 11(1):5. Rosenberg AS, Brunson A, Tuscano J, Jonas BA, Hoeg R, Wun T, Keegan THM. PMID: 33414400; PMCID: PMC7791054.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    24. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):453-458. Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. PMID: 32171691; PMCID: PMC8530379.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    25. Management of neutropenic fever during a transition from traditional hematology/oncology service to hospitalist care. WMJ. 2014 Apr; 113(2):53-8. Raghavendra M, Hoeg RT, Bottner WA, Agger WA. PMID: 24908899.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Measuring the impact of a restrictive transfusion guideline in patients with acute myeloid leukaemia. Vox Sang. 2013 Jul; 105(1):81-4. Hoeg RT, Leinoe EB, Andersen P, Klausen TW, Birgens HS. PMID: 23368963.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    27. [Complete remission of diffuse large B-cell lymphoma of the stomach after eradication of Helicobacter pylori]. Ugeskr Laeger. 2011 Sep 26; 173(39):2425-6. Høeg RT, Skau AM, Nørgaard P, Hansen PB. PMID: 21958489.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    28. Publication outcomes of phase II oncology clinical trials. Am J Clin Oncol. 2009 Jun; 32(3):253-7. Hoeg RT, Lee JA, Mathiason MA, Rokkones K, Serck SL, Crampton KL, Emmel AE, Severson EA, Go RS. PMID: 19349853.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    Rasmus's Networks
    Concepts (106)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (24)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-34-g86efa0e9 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California